Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role. As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a ...

25 March 2026 Announcement no. 3 Pharma Equity Group A/S - Annual Report 2025 Pharma Equity Group A/S - Annual Report 2025 – Highlights of the year Today, the Board of Directors of Pharma Equity Group A/S reviewed and approved the Company's Annual Report for 2025, the key highlights of which are as follows: Main figures for 2025 | 2025 | 2024 | | --- | --- | | TDKK | TDKK | In 2025, Reponex Pharmaceuticals A/S obtained regulatory approval to initiate a pivotal Phase 2 trial of RNX-011 for the treatment of s ...

Merck to spend $6.7 billion to buy Terns Pharmaceuticals, which is developing an oral treatment for leukemia. ...

CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel, therapeutics for autism spectrum disorder and related conditions is pleased to announce that it has selected Novotech as the contract research organization (“CRO”) for the Company’s upcoming Phase I for its lead drug candidate MB-204. Novotech is an international ...

Pharma giant Merck is buying U.S. biotech firm Terns Pharmaceuticals for $6.7 billion, the company said Wednesday.This is the third multibillion-dollar acquisition for Merck over the past year as the company looks to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028. Terns shares rose 5.3% while Merck stock was largely flat in premarket trading. This is breaking news. Please refresh for updates. ...

The United Laboratories International Holdings Ltd. (TUL) and Novo Nordisk A/S (NVO) have announced promising topline results from a phase 2 trial of investigational drug UBT251 in Chinese patients with type 2 diabetes.UBT251 is a triple agonist targeting the GLP-1, GIP, and glucagon receptors (triple G) and is being co-developed by United Biotechnology, a subsidiary of United Labs, and Novo Nordisk. Triple G agonists are designed to treat type 2 diabetes and obesity. In the phase 2 trial, conducted by Uni ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Most Profitable S&P 500 Stocks to Buy Now. On March 20, 2026, Citi raised the price target on Merck & Co., Inc. (NYSE:MRK) to $125 from $120 and maintained a Neutral rating. On March 18, 2026, Merck’s Animal Health division announced that the FDA approved an expanded label for Bravecto Quantum in dogs, adding treatment and control for additional tick species for up to 12 months with a single injection. The product, first approved in July 2025, remains availab ...

Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML Merck to hold investor call at 8 a.m. EDT today RAHWAY, N.J. and FOSTER CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the companies have entered into a ...

Boehringer Ingelheim Pharmaceuticals (:) Update / briefing March 25, 2026 05:30 AM ET Company ParticipantsArmin Wiesler - Member of the Board of Managing DirectorsChristoph Moritz - JournalistFrank Hübler - Head of Corporate Finance, Accounting, Controlling, and TaxMichael Schmelmer - Vice Chairman of the Board of Managing DirectorsPaola Casarosa - Member of the Board of Managing Directors (Innovation Unit)Ralf Heidenreich - JournalistShashank Deshpande - Chairman of the Board of Managing Directors and Head ...

Key TakeawaysThe U.S. has delivered a 15-point ceasefire proposal to Iran via Pakistani officials, including provisions for sanctions relief, a nuclear rollback, and guaranteed access to the Strait of Hormuz.BlackRock (BLK) CEO Larry Fink warned that a spike in oil prices to $150 per barrel would trigger a global recession, as energy costs continue to pressure European economies.European equity markets rallied on hopes of a diplomatic breakthrough, with Germany’s DAX rising 1.5% and the STOXX 600 gaining 0. ...